OOIR: Observatory of International Research

Papers

(The TQCC of Neurology-Neuroimmunology & Neuroinflammation is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Elevated ITGAX/CD11c in CSF-Derived Extracellular Vesicles Reflects Disability Progression in Multiple Sclerosis	156
Clinical Presentation, Management, and Diagnostic Performance of 2021 Criteria for Paraneoplastic Neurologic Syndromes in Childhood	135
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment	108
Relapsing and Immune-Responsive Paroxysmal Jaw Clonus With Blepharospasm and Sialorrhea Associated With D2R Autoantibodies	91
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod	85
Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology	78
Immunohistologic Features of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia	74
Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis	73
A 28-Year-Old Woman With Left-Sided Weakness and Atypical MRI Lesions	72
Antibody-Negative Autoimmune Encephalitis	70
Pro-Inflammatory Molecules Implicated in Multiple Sclerosis Divert the Development of Human Oligodendrocyte Lineage Cells	67
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD	62
Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis	61
CSF Concentrations of CXCL13 and sCD27 Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis	59
Relapsing-Remitting Immunotherapy Responsive Small-Fiber Neuropathy	57
Should We Measure CSF Complement Levels in Patients With MOGAD?	56
Peripheral HLA-DR ^hi CD141 ⁺ Classical Monocytes Predict Relapse Risk and Worsening in Multiple Sclerosis	55
TNF-Blockade for Primary Stroke Prevention in Adenosine Deaminase 2 Deficiency	54
Plasma N -Glycan Profiling Enhances Diagnostic Precision in Multiple Sclerosis, AQP4-Ab NMOSD, and MOGAD	53
Acute Paresthesia and Ataxia in a Child	53
Baicalin Promotes CNS Remyelination via PPARγ Signal Pathway	52
Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection	52
Cell-Free DNA Derived From Neutrophils Triggers Type 1 Interferon Signature in Neuromyelitis Optica Spectrum Disorder	52
Intrathecal Inflammatory Profile and Gray Matter Damage Predict Progression Independent of Relapse Activity in Early Multiple Sclerosis	51
Peripheral Immune Profiles Predict ALS Progression in an Age- and Sex-Dependent Manner	50

Synaptic Protein Loss in Extracellular Vesicles Reflects Brain and Retinal Atrophy in People With Multiple Sclerosis	50
Toward Precision Phenotyping of Multiple Sclerosis	50
Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria	49
Treatment With Erythropoietin for Patients With Optic Neuritis	49
CXCL10/IgG1 Axis in Multiple Sclerosis as a Potential Predictive Biomarker of Disease Activity	47
Novel Cell-Based Assay for Alpha-3 Nicotinic Receptor Antibodies Detects Antibodies Exclusively in Autoimmune Autonomic Ganglionopathy	46
Patients With Severe Multiple Sclerosis Exhibit Functionally Altered CD8 ⁺ Regulatory T Cells	46
Neuropsychological Testing in Autoimmune Encephalitis: A Scoping Review	46
Retinal Optical Coherence Tomography in Neuromyelitis Optica	46
Proteomics Analysis Moves the Needle by Generating Clinical Diagnostic Markers	46
Immunotherapy-Responsive Neuropathic Pain and Allodynia in a Patient With Glycine Receptor Autoantibodies	45
Trigeminal Nerve Involvement in Bulbar-Onset Anti-IgLON5 Disease	45
Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG–Associated Experimental Autoimmune Encephalomyelitis	44
Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis	44
Clinical Manifestations and Treatment Responses in Pediatric Neurofascin 155-IgG4 Autoimmune Nodopathy	43
Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis	40
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis	40
Comparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABA _B R Antibodies	39
Clinical Features of Children With MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders	36
Epstein-Barr Virus in the Cerebrospinal Fluid and Blood Compartments of Patients With Multiple Sclerosis and Controls	36
Applying the Supporting Features for MOGAD Diagnosis to Patients With Multiple Sclerosis	36
Increased Intracranial Pressure in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	35
Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity	35
The Role of Complement Activation in IgM M-Protein–Associated Neuropathies	35
Pediatric MOG-Ab–Associated Encephalitis	35
Cognitive Impairment, Associated Clinical Factors, and MR Volumetric Measures in Myelin Oligodendrocyte Glycoprotein-IgG–Associated Disease	35
A 42-Year-Old Woman With Rapidly Expanding White Matter Lesions	35
“Will the Real Demyelinating Disorder Please Stand Up?”	34
Absence of Systemic Oxidative Stress and Increased CSF Prostaglandin F2α in Progressive MS	34
Paraneoplastic Cerebellar Degeneration With P/Q-VGCC vs Yo Autoantibodies	33
Spironolactone Targets Retinoid X Receptor γ to Promote Myelin Sheath Regeneration	33
Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry	33
Acknowledgment to Reviewers	33
Peptides From the Variable Domain of Immunoglobulin G as Biomarkers in Chronic Inflammatory Demyelinating Polyradiculoneuropathy	33
miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis	32
Deep Phenotyping of Neurologic Postacute Sequelae of SARS-CoV-2 Infection	32
Chronic Dengue Virus Encephalitis	32
Clinicopathologic Profiles of Sporadic Late-Onset Nemaline Myopathy	32
Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis	31
Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study	31
Elsberg Syndrome Secondary to Cytomegalovirus Infection in an Immunocompetent Patient	30
Neurologic Manifestations of Common Variable Immunodeficiency	30
Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models	30
Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies	30
Clinical and Immunologic Effects of Paraprobiotics in Long-COVID Patients	29
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab	29
Cryptococcal Meningitis Reported With Fingolimod Treatment	28
Racial and Ethnic Disparities in the Incidence of Anti-NMDA Receptor Encephalitis	28
Lymphocyte Dynamics and the Emergence of Secondary Autoimmunity Following Immune Reconstitution Therapies in Multiple Sclerosis	28
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies	28

B Cells in the CNS at Postmortem Are Associated With Worse Outcome and Cell Types in Multiple Sclerosis	27
Recovery From COVID-19 in Multiple Sclerosis	27
Distinguishing Transient From Persistent Brain Structural Changes in Pediatric Patients With Acute Disseminated Encephalomyelitis	26
Pregnancy and Infant Outcomes in Multiple Sclerosis	26
Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis	26
MRI Features and Their Association With Outcomes in Children With Anti-NMDA Receptor Encephalitis	26
Alterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients With Multiple Sclerosis	26
mRNA COVID-19 Vaccination Does Not Exacerbate Symptoms or Trigger Neural Antibody Responses in Multiple Sclerosis	25
Clinical Characterization and Ancillary Tests in Susac Syndrome	25
Ten Years of Neurology ® Neuroimmunology & Neuroinflammation	25
Natalizumab-Associated Progressive Multifocal Leukoencephalopathy After Natalizumab Extended Interval Dosing Therapy in Japan	24
Chronic Active Lesions and Larger Choroid Plexus Explain Cognition and Fatigue in Multiple Sclerosis	24
Progressive Encephalomyelopathy in an Older Man	24
Unknown Immunoregulatory Effects of FcRn Inhibition by Efgartigimod in Myasthenia Gravis	24
Proinflammatory Effect of Mesenchymal Stem Cells From Patients With Multiple Sclerosis	24
CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments	24
Neuropsychological Testing in Autoimmune Encephalitis	23
Area Postrema Syndrome in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy	23
Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis	23
Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies	23
Retinal Damage and Visual Network Reconfiguration Defines Visual Function Recovery in Optic Neuritis	23
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis	22
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival	22
HLA-DRB115:01 and the MERTK* Gene Interact to Selectively Influence the Profile of MERTK-Expressing Monocytes in Both Health and MS	22
Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (I)	22
Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides	22
Iatrogenic Cerebral Amyloid Angiopathy–Related Inflammation	22
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors	22
Pediatric MOG-Ab–Associated Encephalitis	22
Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis	22
PET Study of Microglial Activation in Kleine-Levin Syndrome	22
Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3	21
Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy	21
Multiple Sclerosis in the Emergency Department	21
Progressive Myelitis in a 63-Year-Old Woman	21
Extensive Corticospinal Tract Involvement in a Patient With Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy	21
Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort	20
Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean	20
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy	20
Imaging Characteristics of Choroid Plexuses in Presymptomatic Multiple Sclerosis	20
Paraneoplastic Brachial Amyotrophic Diplegia With Favorable Outcome and Anti-Ank3 Antibodies	20
SARS-CoV-2–Specific Immune Responses in Patients With Postviral Syndrome After Suspected COVID-19	20
Cerebellar Ataxia With Anti-DNER Antibodies	20
Ravulizumab and Efgartigimod in Myasthenia Gravis	20
CNS Antigen-Specific Neuroinflammation Attenuates Ischemic Stroke With Involvement of Polarized Myeloid Cells	20
Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis	20
CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity	20
Mutational Profile in 75 Patients With Anti–Myelin-Associated Glycoprotein Neuropathy	19
Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders	19
A 79-Year-Old Woman With Worsening Headaches and Pachymeningeal Enhancement	19
Genomic and Serologic Characterization of Enterovirus A71 Brainstem Encephalitis	19
Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD	19
Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis	19
Microstructural Damage and Repair in the Spinal Cord of Patients With Early Multiple Sclerosis and Association With Disability at 5 Years	19
Antibody Investigations in 2,750 Children With Suspected Autoimmune Encephalitis	19
Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis	19
Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure	18
Comparison of Structural Changes in Nodding Syndrome and Other Epilepsies Associated With Onchocerca volvulus	18
Multiple Sclerosis Patient Macrophages Impaired Metabolism Leads to an Altered Response to Activation Stimuli	18
Single-Cell Multi-Omics Map of Cell Type–Specific Mechanistic Drivers of Multiple Sclerosis Lesions	18
Inflammatory Activity After Diverse Fertility Treatments	18
Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis	18
Temporal Lobe Epilepsy Associated With Glutamic Acid Decarboxylase Antibodies	18
Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade	18
COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis	18